A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma

Histone deacetylase (HDAC) inhibitors are effective in MYCN-driven cancers, because of a unique need for HDAC recruitment by the MYCN oncogenic signal. However, HDAC inhibitors are much more effective in combination with other anti-cancer agents. To identify novel compounds which act synergistically...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Belamy B., Kleynhans, Ane, Mittra, Rituparna, Kim, Patrick Y., Holien, Jessica K., Nagy, Zsuzsanna, Ciampa, Olivia C., Seneviratne, Janith A., Mayoh, Chelsea, Raipuria, Mukesh, Gadde, Satyanarayana, Massudi, Hassina, Wong, Iris Poh Ling, Tan, Owen, Gong, Andrew, Suryano, Aldwin, Diakiw, Sonya M., Liu, Bing, Arndt, Greg M., Liu, Tao, Kumar, Naresh, Sangfelt, Olle, Zhu, Shizhen, Norris, Murray D., Haber, Michelle, Carter, Daniel R., Parker, Michael W., Marshall, Glenn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016666/
https://www.ncbi.nlm.nih.gov/pubmed/33658627
http://dx.doi.org/10.1038/s41388-021-01712-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016666/
https://www.ncbi.nlm.nih.gov/pubmed/33658627
http://dx.doi.org/10.1038/s41388-021-01712-w

Ejemplares similares